NasdaqGS - Delayed Quote • USD
Evotec SE (EVO)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 5:39 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 4 | 5 |
Avg. Estimate | -0.1 | -0.09 | -0.22 | 0.08 |
Low Estimate | -0.21 | -0.2 | -0.8 | -0.6 |
High Estimate | -0.02 | 0.01 | 0.1 | 0.46 |
Year Ago EPS | -0.04 | -0.04 | -0.25 | -0.22 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 5 | 5 |
Avg. Estimate | 222.57M | 219.03M | 934.73M | 1.11B |
Low Estimate | 213.62M | 215.38M | 903.89M | 1.03B |
High Estimate | 232.5M | 224.64M | 979.21M | 1.18B |
Year Ago Sales | 229.12M | 185.92M | 844.85M | 934.73M |
Sales Growth (year/est) | -2.90% | 17.80% | 10.60% | 19.20% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.11 | -0.04 | -0.05 | -0.03 |
EPS Actual | -0.04 | -0.04 | -0.12 | -0.05 |
Difference | -0.15 | 0 | -0.07 | -0.02 |
Surprise % | -136.40% | 0.00% | -140.00% | -66.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.1 | -0.09 | -0.22 | 0.08 |
7 Days Ago | -0.04 | -0.01 | 0.11 | 0.33 |
30 Days Ago | -0.04 | -0.01 | 0.12 | 0.34 |
60 Days Ago | -0.04 | -0.01 | 0.12 | 0.34 |
90 Days Ago | -0.04 | -0.01 | 0.16 | 0.34 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 1 | 1 | 1 | 1 |
Up Last 30 Days | 1 | 1 | 1 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | 2 | -- |
Growth Estimates
CURRENCY IN USD | EVO | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -150.00% | -- | -- | 6.50% |
Next Qtr. | -125.00% | -- | -- | 12.00% |
Current Year | 12.00% | -- | -- | 5.30% |
Next Year | 136.40% | -- | -- | 13.10% |
Next 5 Years (per annum) | 235.60% | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | HC Wainwright & Co.: Buy to Buy | 4/25/2024 |
Maintains | HC Wainwright & Co.: Buy to Buy | 8/31/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 7/12/2023 |
Upgrade | Morgan Stanley: Equal-Weight to Overweight | 6/23/2023 |
Downgrade | B of A Securities: Buy to Neutral | 6/16/2023 |
Upgrade | Citigroup: Neutral to Buy | 6/8/2023 |
Related Tickers
SBFM Sunshine Biopharma, Inc.
0.9500
+17.66%
LFCR Lifecore Biomedical, Inc.
6.60
-0.68%
OPTN OptiNose, Inc.
0.8604
-4.93%
AMRX Amneal Pharmaceuticals, Inc.
5.87
-0.51%
HCM HUTCHMED (China) Limited
18.16
-4.37%
NBIX Neurocrine Biosciences, Inc.
135.99
-1.28%
MOB.ST Moberg Pharma AB (publ)
33.16
-2.87%
KMDA Kamada Ltd.
5.15
-0.96%
ITCI Intra-Cellular Therapies, Inc.
73.26
+1.57%
CPH.TO Cipher Pharmaceuticals Inc.
8.50
0.00%